On December 16, 2021 Alpine Immune Sciences and Ireland’s Horizon Therapeutics reported a licensing and collaborative research and development agreement valued at up to $1.5 billion to generate up to four preclinical candidates for autoimmune and inflammatory diseases (Press release, Biosortia Pharmaceuticals, DEC 16, 2021, View Source [SID1234607737]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Horizon will have exclusive rights to develop and commercialize the candidates from Seattle-based Alpine’s unique discovery platform. Overall, the collaboration and licensing agreement between the two cross-Atlantic companies includes a lead, potential first-in-class preclinical candidate, as well as a research collaboration to jointly develop the additional novel candidates.